Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07722832

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation

As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to evaluate the clinical impact of support provided by Quitoxil® as an adjunct to conventional management for patients undergoing smoking cessation who have a tobacco use disorder.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women aged between 18 and 65
  • Who have understood and signed the informed consent form
  • With a tobacco use disorder according to the diagnostic criteria of the DSM-5 and ICD-10.
  • Daily smoker of manufactured or hand-roll , consuming at least 5 cigarettes per day for ≥ 12 months.
  • Expressing a desire to stop smoking
  • Having undergone a motivational interview, having completed, or completing during the inclusion visit, a Richmond Test with a score > 5 as part of the smoking cessation process.
  • Starting, at the inclusion visit or at , first-line nicotine replacement therapy (NRT), with a duration of use not exceeding one month prior to inclusion.
  • Available to attend the scheduled visits and assessments, including setting aside 10 to 30 minutes per week throughout the study.
  • Owns a compatible smartphone (iOS ≥ 13.4 or Android ≥ 6.0) and has a valid email address.
  • Understand and be proficient in the French language, and be able to understand the study instructions.
  • Enrolled in or covered by a social security scheme, in accordance with local requirements

Exclusion criteria

  • Individuals who, at the time of inclusion ( ), have been receiving another form of non-pharmacological support for smoking cessation for more than one month (e.g. cognitive-behavioural therapy, psychotherapy, therapeutic education programmes, hypnosis, acupuncture, support groups, digital apps or tools to aid cessation, helplines, or any other behavioural or non-pharmacological intervention).
  • Anyone deemed by the investigator to lack autonomy.
  • Difficulties using a smartphone
  • Presenting with severe, unstabilised psychiatric disorders (defined as a patient admitted to a psychiatric ward), in particular: acute or transient psychotic disorders, bipolar disorder type I or II, other unstabilised bipolar or related disorders.
  • Participating in another interventional research trial (with the exception of the IMPULSION programme - Implementation of lung cancer screening in the population)
  • A person subject to a compulsory treatment order under a court order.
  • A person under guardianship, curatorship, judicial protection, or any other administrative or judicial measure resulting in a partial or total deprivation of rights and freedoms.

Treatment and study plan

Quitoxil®

Device

Quitoxil® is the first CE-marked (Class I) digital medical device in France dedicated to helping people quit smoking. Its support programme, structured around two modules and eight themes, offers an integrative approach specifically developed in line with the principles of cognitive behavioural therapy and facilitates contact with patient experts certified in addiction treatment

Nicotine Replacement Therapies

Drug

Nicotine replacement therapies (NRTs) are treatments that deliver controlled doses of nicotine without tobacco to help people reduce withdrawal symptoms and quit smoking.

Primary outcomes

  1. Clinical impact of using the Quitoxil device in the management of smoking cessation

    Time frame: 6 months

    Self-reported smoking abstinence at 6 months (24 weeks) for 7 consecutive days prior to the visit, confirmed by a biochemical measurement of exhaled carbon monoxide (CO) ≤ 10 ppm.

Sponsors and collaborators

Lead sponsor

KLAVA Innovation

Industry

Registry information

Official study title

Evaluation of the Impact of the QUITOXIL® System on Smoking Cessation in Patients With Tobacco Use Disorder : a Randomized Controlled Clinical Trial.

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 23, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.